Jennifer Pritzker Sells 221,166 Shares of Alphatec (NASDAQ:ATEC) Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) major shareholder Jennifer Pritzker sold 221,166 shares of the firm’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $21.20, for a total value of $4,688,719.20. Following the completion of the sale, the insider directly owned 10,673,879 shares of the company’s stock, valued at approximately $226,286,234.80. This trade represents a 2.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Alphatec Price Performance

Shares of NASDAQ:ATEC traded up $0.23 on Wednesday, reaching $20.90. 3,368,927 shares of the company were exchanged, compared to its average volume of 2,125,982. The company has a current ratio of 1.99, a quick ratio of 1.24 and a debt-to-equity ratio of 43.02. Alphatec Holdings, Inc. has a 1-year low of $8.69 and a 1-year high of $22.66. The firm has a market cap of $3.10 billion, a price-to-earnings ratio of -20.10 and a beta of 1.08. The company has a 50-day moving average of $18.04 and a 200-day moving average of $14.95.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings data on Thursday, October 30th. The medical technology company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.09. The company had revenue of $196.50 million during the quarter, compared to analyst estimates of $182.78 million. The firm’s revenue for the quarter was up 30.4% on a year-over-year basis. During the same quarter last year, the business earned ($0.28) EPS. Equities analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ATEC has been the topic of a number of research reports. Morgan Stanley set a $23.00 price target on Alphatec in a report on Tuesday, December 2nd. Piper Sandler reissued an “overweight” rating and issued a $25.00 target price (up previously from $20.00) on shares of Alphatec in a report on Friday, October 31st. Canaccord Genuity Group lifted their price target on Alphatec from $20.00 to $25.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Barclays boosted their price objective on shares of Alphatec from $22.00 to $23.00 and gave the stock an “overweight” rating in a research report on Monday, November 3rd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Alphatec in a report on Monday. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Alphatec presently has a consensus rating of “Moderate Buy” and an average target price of $22.45.

Institutional Trading of Alphatec

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Aster Capital Management DIFC Ltd purchased a new stake in Alphatec during the 3rd quarter worth about $34,000. Osterweis Capital Management Inc. purchased a new position in Alphatec in the 2nd quarter valued at about $37,000. Nisa Investment Advisors LLC lifted its holdings in Alphatec by 22.4% in the 2nd quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock valued at $63,000 after purchasing an additional 1,045 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Alphatec during the 3rd quarter worth about $73,000. Finally, FORA Capital LLC purchased a new stake in shares of Alphatec during the first quarter worth about $102,000. 66.35% of the stock is currently owned by hedge funds and other institutional investors.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.